GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioTelemetry Inc (NAS:BEAT) » Definitions » Cash Conversion Cycle

BioTelemetry (BioTelemetry) Cash Conversion Cycle : 24.65 (As of Sep. 2020)


View and export this data going back to 2008. Start your Free Trial

What is BioTelemetry Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

BioTelemetry's Days Sales Outstanding for the three months ended in Sep. 2020 was 54.87.
BioTelemetry's Days Inventory for the three months ended in Sep. 2020 was 12.46.
BioTelemetry's Days Payable for the three months ended in Sep. 2020 was 42.68.
Therefore, BioTelemetry's Cash Conversion Cycle (CCC) for the three months ended in Sep. 2020 was 24.65.


BioTelemetry Cash Conversion Cycle Historical Data

The historical data trend for BioTelemetry's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioTelemetry Cash Conversion Cycle Chart

BioTelemetry Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.38 -4.84 -0.92 4.22 13.12

BioTelemetry Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.18 18.44 20.39 25.43 24.65

Competitive Comparison of BioTelemetry's Cash Conversion Cycle

For the Diagnostics & Research subindustry, BioTelemetry's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioTelemetry's Cash Conversion Cycle Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BioTelemetry's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where BioTelemetry's Cash Conversion Cycle falls into.



BioTelemetry Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

BioTelemetry's Cash Conversion Cycle for the fiscal year that ended in Dec. 2019 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=45.55+14.46-46.89
=13.12

BioTelemetry's Cash Conversion Cycle for the quarter that ended in Sep. 2020 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=54.87+12.46-42.68
=24.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioTelemetry  (NAS:BEAT) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


BioTelemetry Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of BioTelemetry's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


BioTelemetry (BioTelemetry) Business Description

Traded in Other Exchanges
N/A
Address
1000 Cedar Hollow Road, Suite 102, Malvern, PA, USA, 19355
BioTelemetry Inc provides monitoring services and digital population health management for healthcare providers, medical device manufacturing, and centralized core laboratory services for clinical research. It operates under healthcare, technology, and research segments. The Healthcare segment is focused on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. The Research segment is engaged in central core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials and the Technology segment, focuses on the development, manufacturing, testing, and marketing of cardiovascular and blood glucose monitoring devices to medical companies, clinics and hospitals.
Executives
Kirk E Gorman director 367 SOUTH GULPH ROAD, KING PRUSSIA PA 19406
Stephen Rietiker director C/O BIOTELEMETRY, INC., 1000 CEDAR HOLLOW RD. SUITE 102, MALVERN PA 19355
Tiffany Olson director C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Joseph A. Frick director ONE COMMERCE SQUARE 2005 MARKET ST., SUITE 3300 19103 PR 19073
Laura N. Dietch director 1000 CEDAR HOLLOW RD. SUITE 102 MALVERN PA 19355
Anthony James Conti director 76 GOLFVIEW DRIVE, IVYLAND PA 18974
Rebecca W Rimel director 345 PARK AVENUE, NEW YORK NY 10154
Robert J. Rubin director 7901 SPRINGER ROAD, BETHESDA MD 20817
Hill Colin director 196 BROADWAY CAMBRIDGE MA 02139
Andrei G Stoica officer: SVP & CTO 1000 CEDAR HOLLOW ROAD, MALVERN PA 19355
Joseph H Capper director, officer: President & CEO BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Manish Wadhwa officer: SVP & CMO 1000 CEDAR HOLLOW ROAD MALVERN PA 19355
Fred Broadway officer: President BioTel Heart BIOTELEMETRY, INC. 1000 CEDAR HOLLOW ROAD, #102 MALVERN PA 19355
Daniel Wisniewski officer: SVP, Technical Operations BIOTELEMETRY, INC. 1000 CEDAR HOLLOW ROAD, #102 MALVERN PA 19355
Heather C Getz officer: EVP, CFO & CAO BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355